GNFTF Stock Chart & Stats
$15.75
$5.20(48.37%)
At close: 4:00 PM EDT
$15.75
$5.20(48.37%)
Day’s Range― - ―
52-Week Range$3.72 - $16.50
Previous CloseN/A
Volume200.00
Average Volume (3M)0.00
Market Cap
$463.27M
Enterprise Value$595.85M
Total Cash (Recent Filing)$113.82M
Total Debt (Recent Filing)$179.28M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Apr 08, 2027EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding50,099,620
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue11.24
Enterprise Value/Gross Profit589.36
Enterprise Value/Ebitda-32.63
Forecast
1Y Price Target
$16.82Price Target Upside6.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.35
Revenue Forecast (FY)$99.40M
Bulls Say, Bears Say
Bulls Say
2025 Revenue GrowthThe sharp 2025 revenue rebound indicates that Genfit can generate meaningful transaction or partnership-related income when pipeline and diagnostic activities advance. If progress continues, stronger top-line performance could support development investment and improve strategic leverage with potential partners.
Specialized Liver-Disease FocusA focused position in metabolic and liver diseases gives Genfit specialized scientific capabilities and a coherent development strategy. Its combination of non-invasive diagnostics, biomarkers, and therapeutics can create strategic value across related programs rather than relying on a single type of asset.
Multiple Monetization RoutesGenfit has several potential routes to monetize its research platform, including collaborations, milestone payments, asset transactions, grants, and tax credits. This structure can provide strategic flexibility and reduce reliance on recurring product sales while programs remain in clinical development.
Bears Say
Return To Heavy LossesThe return to substantial operating and net losses shows that recent revenue growth has not translated into durable profitability. Historical swings from strong profitability to losses also make earnings power difficult to forecast and increase dependence on future pipeline progress or transactions.
Negative Equity And Higher DebtNegative shareholders’ equity combined with materially higher debt signals weakened capitalization and reduced financial flexibility. If losses continue, Genfit may have less capacity to fund development internally, absorb setbacks, or negotiate from strength when arranging future financing.
Renewed Cash BurnThe reversal to negative operating and free cash flow indicates that the business is again consuming cash rather than self-funding its activities. Several prior years also recorded sizable cash outflows, increasing the importance of financing, partnerships, or successful monetization events.
Genfit News
GNFTF FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was $3.72 and its highest was $16.50 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is $463.27M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 08, 2027 which is in 177 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 28, 2026. The company reported -$0.224 earnings per share for the quarter, missing the consensus estimate of -$0.179 by -$0.045.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.41.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,099,620 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -$0.224 in its last earnings report, missing expectations of -$0.179. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GNFTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genfit SA
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
GNFTF Stock 12 Month Forecast
Average Price Target
$16.82
▲(6.79% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.87% Public Companies and
Individual Investors